March 7, 2025 02:57 PM ESTUpdated 04:48 PM
Pharma
FDA+

FDA ap­proves Neu­rotech cell ther­a­py to slow a rare de­gen­er­a­tive eye dis­ease 

Lei Lei Wu

News Reporter

The FDA on Thurs­day ap­proved Neu­rotech Phar­ma­ceu­ti­cals’ cell ther­a­py for an eye dis­ease known as mac­u­lar telang­iec­ta­sia type 2, which caus­es …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Trump think tank res­ur­rects in­ter­na­tion­al drug pric­ing mod­el to go af­ter 'glob­al free­load­ing'

FDA staff re­turn to White Oak cam­pus en masse af­ter Trump ad­min­is­tra­tion push

George Church spin­out de­vel­op­ing ge­nom­i­cal­ly re­cod­ed or­gan­isms cuts most em­ploy­ees

As­traZeneca broad­ens pres­ence in Chi­na, promis­ing $8B+ to Har­bour and Syneron

Six­teen-year-old dies af­ter re­ceiv­ing Sarep­ta’s Duchenne gene ther­a­py

Il­lu­mi­na was built on DNA. Its fu­ture could be bi­ol­o­gy’s next big wave

A service from the Financial Times